Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ni Xie

Matched on OpenAlex author ID A5102497350. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 9

  1. Formosanin C Induces ROS/p38-Mediated Cell Death While Also Promoting Protective Autophagy in Pancreatic Cancer. Co-author DOI 10.1002/ptr.70094↗
  2. Peritumoral and Intratumoral Texture Features Based on Multiparametric MRI and Multiple Machine Learning Methods to Preoperatively Evaluate the Pathological Ou… Co-author DOI 10.1002/jmri.28538↗
  3. Preoperative Extrapancreatic Extension Prediction in Patients with Pancreatic Cancer Using Multiparameter MRI and Machine Learning-Based Radiomics Model. Co-author DOI 10.1016/j.acra.2022.09.017↗
  4. Identification of m7G-Related LncRNA Signature for Predicting Prognosis and Evaluating Tumor Immune Infiltration in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/diagnostics13101697↗
  5. Suppression of Wnt/β-catenin Signaling in PDAC via METTL16-mediated N6-methyladenosine Modification of DVL2. Co-author DOI 10.7150/jca.85860↗
  6. Circular RNA circ_0047744 suppresses the metastasis of pancreatic ductal adenocarcinoma by regulating the miR-21/SOCS5 axis. Co-author DOI 10.1016/j.bbrc.2022.03.082↗
  7. Identification and Validation of Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Necroptosis-Related Genes. Co-author DOI 10.3389/fgene.2022.919638↗
  8. RELA-induced MiR-21 Exerts Oncogenic Effects on PDAC via Targeting of ARHGAP24. Co-author DOI 10.7150/jca.73690↗
  9. Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Co-author DOI 10.18632/aging.203575↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lanting Yu · 6 shared papers, 2022–2023 · strength 1.08
  2. Baiwen Li · 5 shared papers, 2022–2023 · strength 0.89
  3. Xuhui Fan · 3 shared papers, 2021–2023 · strength 0.52
  4. Haoran Xie · 3 shared papers, 2022 · strength 0.48
  5. Hao Liu · 2 shared papers, 2023 · strength 0.36
  6. Baiwen Li · 2 shared papers, 2023 · strength 0.36
  7. Xingpeng Wang · 2 shared papers, 2022–2023 · strength 0.34
  8. Qiuyan Zhao · 2 shared papers, 2022 · strength 0.32
  9. Chunmei Wen · 1 shared paper, 2025 · strength 0.25
  10. Jie Deng · 1 shared paper, 2025 · strength 0.25
  11. Qingqing Ruan · 1 shared paper, 2025 · strength 0.25
  12. Deyuan Chen · 1 shared paper, 2025 · strength 0.25
  13. Jiawei Lu · 1 shared paper, 2023 · strength 0.22
  14. Han Wang · 1 shared paper, 2023 · strength 0.18
  15. Li Cheng · 1 shared paper, 2022 · strength 0.16
  16. Hangcheng Guo · 1 shared paper, 2021 · strength 0.16
  17. Haotian Fu · 1 shared paper, 2021 · strength 0.16
  18. Yunfeng Shan · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.